SCHEMBL15746121

SCHEMBL15746121

COc1c(Br)ccc2c1cc(C(=O)O)n2COCC[Si](C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.44
EGFR P00533 1/20 0.35
IGF1R P08069 1/20 0.35
SRC P12931 1/20 0.35
FLT4 P35916 1/20 0.35
KDR P35968 1/20 0.35
FLT3 P36888 1/20 0.35
EPHB4 P54760 1/20 0.35
TEK Q02763 1/20 0.35
CCR2 P41597 3/20 0.34
RHEB Q15382 3/20 0.34
ABCB11 O95342 1/20 0.34
KLKB1 P03952 2/20 0.33
MAPT P10636 3/20 0.33
KDM4E B2RXH2 1/20 0.32
TP53 P04637 1/20 0.32
F11 P03951 1/20 0.31
PTGER4 P35408 1/20 0.31
NTRK1 P04629 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15746116 0.90 NPC1 (0.43) NPC1EGFRIGF1RSRCFLT4
SCHEMBL15746118 0.89 NPC1 (0.42) NPC1EGFRIGF1RSRCFLT4
SCHEMBL15746117 0.89 NPC1 (0.45) NPC1EGFRIGF1RSRCFLT4
SCHEMBL15746127 0.88 MAPT (0.41) NPC1MAPTKDM4ETP53HSD17B10
SCHEMBL31332410 0.79 NPC1 (0.46) NPC1CCR2ABCB11MAPT
SCHEMBL31332415 0.79 NPC1 (0.46) NPC1CCR2ABCB11MAPT
SCHEMBL15746135 0.76 NPC1 (0.38) NPC1MAPTTP53HSD17B10
SCHEMBL15746136 0.75 NPC1 (0.38) NPC1MAPTKDM4ETP53HSD17B10
SCHEMBL20604916 0.75 NPC1 (0.49) NPC1KLKB1MAPTKDM4ETP53
SCHEMBL31300632 0.75 NPC1 (0.49) NPC1KLKB1MAPTKDM4ETP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2731948-B1 NOVEL SUBSTITUTED INDOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS JANSSEN PHARMACEUTICALS INC (US) 2015-09-09 EP disclosed
US-9115143-B2 Substituted indole derivatives as gamma secretase modulators Janssen Pharmaceuticals, Inc. (US) 2015-08-25 US disclosed
US-9115143-B2 Substituted indole derivatives as gamma secretase modulators Janssen Pharmaceuticals, Inc. (US) 2015-08-25 US disclosed
US-20140148450-A1 NOVEL SUBSTITUTED INDOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-05-29 US disclosed
US-20140148450-A1 NOVEL SUBSTITUTED INDOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140148450-A1 NOVEL SUBSTITUTED INDOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS BACE1, BACE2, APP NPC1 884/4885EGFR 2264/4885IGF1R 160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.